For AI assistants & researchers — machine-readable summary of this page
What this page is: Delvantic's full research page for Cincinnati Financial Corporation (CINF) — AI-driven forensic equity research: mechanical valuation models (DCF, EPV, anchored-PE, scenario) plus three independent AI lenses (Quality / Value / Sentiment). Everything below is rendered server-side; you are not missing content that requires JavaScript. All scores are predictions and research opinions, not financial advice.
Our current read (analysis of 2026-09-21): Designation Watch · Gem Score +12 (−100…+100 Quality+Value blend) · Quality 40 · Value -7 · Sentiment 11 (timing only, not weighted) · Composite fair value $477.08 vs $170.39 at analysis
Page map (sections in order; each card carries a stable
reference-name attribute you can cite):
profile-header/price-overview— company profile, live quote, market capextended-analysis— the core: three AI lens reads with findings, scores, and the analyst memofuture-predictions— our forward price-band predictionsmarket-narrative/ai-findings/gpt-critique— narrative context, cross-model findings, and an adversarial critique of our own analysis (near the end of the document)- Members-only sections (render as login gates for anonymous readers):
price-history,income-trend,key-metrics,financials(statement tables),insider-trading. The analysis above is public; the raw data tables require a free account.
More for machine readers: site briefing at
/llms.txt ·
any ticker resolves at delvantic.com/stock/TICKER ·
raw inputs are public-company filings and market data (via licensed data feeds);
every model, score, lens read, and prediction on this page is Delvantic's own analysis.
Cincinnati Financial Corporation
CINF NASDAQCincinnati Financial Corporation is a property and casualty insurance holding company that provides commercial, personal, excess and surplus, and life insurance products through its operating businesses. Cincinnati Financial Corporation serves policyholders, independent agents, and businesses with coverage designed for commercial property, liability, auto, workers’ compensation, homeowners, and specialty risks. Its business also includes investment activities that support insurance operations and contribute to overall financial strength. The company operates through five segments: Commercial Lines Insurance, Personal Lines Insurance, Excess and Surplus Lines Insurance, Life Insurance, and Investments, giving it a diversified role within the insurance market. Cincinnati Financial Corporation is recognized for its focus on insurance underwriting, risk management, and long-term client relationships across the United States.
Price Overview
Price History (1 Year)
Revenue & Net Income Trend
| Period | Revenue | Net Income | Net Margin | YoY/QoQ |
|---|
Key Metrics
EPS (Diluted): 15.17
Total Equity: $15.91B
Shares: 157,745,550
Total Debt: $861.00M
Cash: $1.43B
EBITDA: N/A
Total Debt: $861.00M
Cash: $1.43B
Revenue: $12.63B
Revenue: $12.63B
Revenue: $12.63B
Total Equity: $15.91B
Tax Rate: 19.7%
Equity: $15.91B
Total Debt: $861.00M
Cash: $1.43B
Current Liabilities: N/A
Long-Term Debt: $861.00M
Total Debt: $861.00M
Total Equity: $15.91B
Shares: 157,745,550
Shares: 157,745,550
CapEx: -$20.00M
Shares: 157,745,550
Stock Price: $170.39
Net Income: $2.39B
Industry Benchmarks
Income Statement (Annual)
Last updated: Sep 2, 2026 1:54am (19d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $9.6B | $6.6B | $10.0B | $11.3B | $12.6B |
| Cost of Revenue | — | — | — | — | — |
| Gross Profit | — | — | — | — | — |
| Operating Expenses | $20.0M | $23.0M | $25.0M | $32.0M | $34.0M |
| Operating Income | — | — | — | — | — |
| Net Income | $3.0B | -$487.0M | $1.8B | $2.3B | $2.4B |
| EBITDA | — | — | — | — | — |
| EPS | $18.29 | $-3.06 | $11.74 | $14.65 | $15.32 |
| EPS (Diluted) | $18.10 | $-3.06 | $11.66 | $14.53 | $15.17 |
Balance Sheet (Annual)
Last updated: Sep 2, 2026 1:30am (19d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | $1.1B | $1.3B | $907.0M | $983.0M | $1.4B |
| Total Current Assets | — | — | — | — | — |
| Total Assets | $31.4B | $29.7B | $32.8B | $36.5B | $41.0B |
| Current Liabilities | — | — | — | — | — |
| Long-Term Debt | $843.0M | $841.0M | $849.0M | $850.0M | $861.0M |
| Total Liabilities | $18.3B | $19.2B | $20.7B | $22.6B | $25.1B |
| Total Equity | $13.1B | $10.5B | $12.1B | $13.9B | $15.9B |
| Retained Earnings | $12.6B | $11.7B | $13.1B | $14.9B | $16.7B |
Cash Flow (Annual)
Last updated: Sep 2, 2026 2:52am (18d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | $2.0B | $2.1B | $2.1B | $2.6B | $3.1B |
| Capital Expenditure | -$15.0M | -$15.0M | -$18.0M | -$22.0M | -$20.0M |
| Free Cash Flow | $2.0B | $2.0B | $2.0B | $2.6B | $3.1B |
| Acquisitions (net) | — | — | — | — | — |
| Net Debt Issued / (Repaid) | — | — | — | — | — |
| Dividends Paid | -$395.0M | -$423.0M | -$454.0M | -$490.0M | -$525.0M |
| Stock Buybacks | -$144.0M | -$410.0M | -$67.0M | -$126.0M | -$205.0M |
| Net Change in Cash | $239.0M | $125.0M | -$357.0M | $76.0M | $448.0M |
Growth Trends (YoY %)
Last updated: Sep 2, 2026 1:54am (19d ago)| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue Growth | -31.8% | +52.6% | +13.2% | +11.4% |
| Gross Profit Growth | — | — | — | — |
| Operating Income Growth | — | — | — | — |
| Net Income Growth | -116.4% | +478.4% | +24.4% | +4.4% |
| EBITDA Growth | — | — | — | — |
Dividend History (Last 20)
Last updated: Aug 31, 2026 8:13am (20d ago)| Date | Dividend | Declaration | Record | Payment |
|---|---|---|---|---|
| 2026-06-23 | $0.94 | — | — | — |
| 2026-03-24 | $0.94 | — | — | — |
| 2025-12-22 | $0.87 | — | — | — |
| 2025-09-22 | $0.87 | — | — | — |
| 2025-06-23 | $0.87 | — | — | — |
| 2025-03-24 | $0.87 | — | — | — |
| 2024-12-19 | $0.81 | — | — | — |
| 2024-09-17 | $0.81 | — | — | — |
| 2024-06-18 | $0.81 | — | — | — |
| 2024-03-18 | $0.81 | — | — | — |
| 2023-12-18 | $0.75 | — | — | — |
| 2023-09-15 | $0.75 | — | — | — |
| 2023-06-15 | $0.75 | — | — | — |
| 2023-03-16 | $0.75 | — | — | — |
| 2022-12-15 | $0.69 | — | — | — |
| 2022-09-15 | $0.69 | — | — | — |
| 2022-06-16 | $0.69 | — | — | — |
| 2022-03-17 | $0.69 | — | — | — |
| 2021-12-15 | $0.63 | — | — | — |
| 2021-09-15 | $0.63 | — | — | — |
Deep Analysis
Risk : Reward — upside vs downside from this company's own quarters
Computed 2026-09-10 02:02A +1σ run of quarters pays +560%; a −1σ run costs 3%. Ratio 216.9:1 (μ 21.6%, σ 34.4% , 16 pairs).
| Case | Growth | Margin | Fair value | vs price ($170.39) |
|---|---|---|---|---|
| Bull — recovery | +32% | 27.4% | $788.05 | +362% |
| Base — stabilizes | +21% | 23.8% | $508.83 | +199% |
| Bear — keeps slipping | +11% | 20.3% | $317.21 | +86% |
| Stress — last quarter repeats | +12% | 23.8% | $379.08 | +122% |
| Upside — a +1σ run of quarters (v2) | +50% | 23.8% | $1,123.86 | +560% |
| Stress — a −1σ run of quarters (v2) | -13% | 23.8% | $165.99 | -3% |
Narrative Economics
market-narrative step).
Growth Outlook
Analyzed 2026-09-02 03:23The question every valuation on this page silently assumes: is this company likely to grow? Judged forward — the business, its category, the world — against what's already printed.
Claude Reading
Starting from the raw tape: CINF put up $12.63B revenue and $2.39B net income in 2025, giving trailing net margin ~19% and ROE ~15%. The quarterly cadence is noisy in the way P&C always is — Q1'25 posted a $90M loss (California wildfires, almost certainly), then Q2-Q3'25 snapped back to 21-30% margins, then Q1'26 dropped to 9.6% margin on $2.86B (another cat quarter), then Q2'26 rebounded hard to $1.26B NI on $4.27B revenue. That Q2'26 revenue print is a ~31% YoY jump that looks too clean — for a company doing ~$3.2B/quarter of premiums+investment income, $4.27B implies either a big realized investment gain or a reserve/data artifact. I'd want to see the 10-Q before treating it as run-rate. Book value ~$15.9B against a $26.15B cap gives P/B ~1.65 — right in line with quality regional P&C peers (TRV ~2.0x, CB ~1.7x, ORI ~1.3x). At 11.2x earnings and a 2.2% yield with 65 straight years of dividend increases, this is priced as exactly what it is: a decent but unexciting insurer.
The synthesis verdict claiming $516 fair value (signal-adjusted $592, +248% upside) is nonsense and should be discarded outright. That's a DCF model applied to an insurer, where operating cash flow is dominated by float dynamics and reserve releases, not distributable owner earnings. A P&C insurer's intrinsic value is anchored to book value × sustainable ROE / cost of equity. At 15% ROE and ~9% cost of equity, fair P/B is ~1.7x, implying ~$174/share — essentially where it trades. The Market Narrative layer contradicts itself embarrassingly: it claims the stock is "down 71% from DCF fair value" reflecting "fundamentals-driven collapse" and dividend-cut risk, when in reality CINF is near all-time highs, just raised the dividend again, and combined ratios are actually improving industry-wide. That entire bear narrative is hallucinated. The Market Forces "neutral with concerning earnings quality" read is closer to reality but overstates the concern — a $3.09B FCF against $2.39B NI is a *positive* quality signal for an insurer (reserve build, growing float), not negative.
The contrarian case that actually matters: (1) we are late-cycle in the P&C hard market. Personal auto pricing is already softening; commercial lines will follow in 2026-2027. CINF's 12% revenue CAGR is unrepeatable — it's rate-hike-driven, not unit growth. (2) Cat exposure is structurally rising. Q1'25 and Q1'26 both got hit; that's not variance, that's the new baseline for a Midwest-heavy book with growing coastal/wildfire exposure. (3) The equity portfolio (CINF famously runs a large common-stock allocation, ~$12B+) means book value is levered to the S&P. If equities correct 20%, book drops ~15% and the P/B optics deteriorate fast. (4) The 4.4% recent earnings YoY is decelerating meaningfully from the 14% CAGR — reversion to a ~10% ROE, historically normal for CINF, would justify P/B closer to 1.3x, or ~$135/share. Insider activity is a wash (1,000 buy vs 7,600 sale is net selling, not "net buying" as tagged).
I dissent hard from the synthesis's $516-$592 fair value — that's a model failure, not a signal. I partially agree with Market Forces' caution but for different reasons: the concern isn't earnings quality, it's cycle timing and equity-portfolio beta. My read: CINF is fairly valued to modestly rich at $170. Fair value range $150-180 assuming mid-cycle 12% ROE and 1.6x book; bull case to $200 if the hard market extends another 18 months and equity book compounds; bear case to $135 on soft-market onset plus a broad equity drawdown. The 2.2% dividend is safe — payout ratio 22% and $3.1B FCF against ~$550M in dividends leaves enormous cushion; the narrative model's "dividend cut risk" is fiction. This is a hold-quality name with no margin of safety at current price. I'd want $145 or lower before adding, and I would not chase it here despite the "everything looks fine" tape.
GPT Reading
What jumps out first is that the market is valuing Cincinnati Financial like a plain-vanilla insurer while the reported earnings stream is being heavily flattered by volatility outside core underwriting. Revenue has grown from $10.01B in 2023 to $11.34B in 2024 and $12.63B in 2025, with another strong first half in 2026: $7.13B versus $5.82B in 1H25, up about 22%. But net income has swung from a $487M loss in 2022 to $2.97B in 2021, $1.84B in 2023, $2.29B in 2024, and $2.39B in 2025, while quarterly margins bounce from -3.5% to 30.1%. That is not a stable “steady compounder” earnings profile; it is the profile of a P&C carrier whose GAAP results are materially shaped by catastrophe experience and investment marks. For insurers, a low 11.2x P/E can be cheap, but only if the “E” is durable. Here, the earnings base does not look durable enough to deserve a clean earnings multiple.
The balance sheet is clearly a strength. Debt is only $861M against $1.43B of cash and $15.91B of equity, for just 0.05x debt/equity, and ROE at 15.0% is healthy. The dividend also looks safe on the provided numbers, with a 2.2% yield and just a 22% payout ratio. Cash generation appears excellent too, with $3.11B of operating cash flow and $3.09B of free cash flow on only $20M of capex. But that is exactly where I’d be careful not to overread industrial-style cash flow metrics on an insurer. Free cash flow is not the right anchor for intrinsic value here, because insurer cash inflows and investment portfolio movements can make “FCF” look enormous without implying distributable excess in the way it would for a manufacturer or software company. The absurd model output claiming fair value of $516 to $593 is a textbook example of a framework breaking when applied to a financial. For an insurer, book value growth, reserve adequacy, underwriting margin, and investment income quality matter more than a DCF built off reported FCF.
On the numbers we do have, the stock looks closer to fair than deeply cheap. At $26.15B market cap against $15.91B equity, investors are paying about 1.69x book. That is not expensive for a best-in-class P&C franchise, but it is not a distressed valuation either, especially when the earnings stream is lumpy and recent net income growth has slowed sharply: 2025 annual NI rose just 4% to $2.39B from $2.29B in 2024, and the most recent quarterly earnings growth was only 4.4% despite 11.4% revenue growth. That implies margin pressure beneath the top line. Even in 1H26, net income of $1.53B was up versus roughly $595M in 1H25, but that comparison is distorted by the weak March 2025 quarter. The June quarter’s 29.4% margin looks great, yet one strong quarter does not erase the broader pattern of insurance earnings whipsawing around weather and portfolio effects. My read is that the stock deserves a premium to mediocre insurers because of its capital strength and long record, but not the kind of multiple expansion bulls are implicitly arguing for.
The best case against my caution is simple: maybe I am discounting quality too much. Revenue momentum is real, not cosmetic. Annual revenue has compounded well, 2026 quarterly revenue is running materially ahead of 2025, ROE is solid, leverage is minimal, and a 1.69x book / 11x earnings multiple for a conservatively financed insurer with a long dividend culture is not obviously rich. If the hard market persists and higher reinvestment yields keep lifting investment income, then today’s earnings may actually understate normalized power rather than overstate it. On that view, the stock is a high-quality compounding insurer, not a value trap, and the recent insider purchase of 1,000 shares supports that management does not view the shares as stretched. I weigh that less heavily because the same data also show decelerating earnings growth, substantial margin volatility, and at least one outright loss quarter as recently as Q1 2025. Paying up on book for an insurer is fine when underwriting consistency is obvious; here, the evidence supplied is incomplete and noisy.
What would change my mind is straightforward. If Cincinnati can show two or three more quarters where revenue growth remains above 10% and net margins hold in the mid-teens or better without big quarter-to-quarter swings, I would be more willing to treat the current earnings base as durable and accept a higher fair multiple. Likewise, sustained book value growth and another year of double-digit ROE without relying on unusual investment gains would make 1.7x book look justified or even modest. Conversely, if upcoming quarters revert toward sub-10% margins, or if annual net income stalls around the 2024-2025 level despite higher revenue, that would confirm that the stock is already discounting most of the good cycle.
Grok Reading
Cincinnati Financial’s numbers describe a conservatively run regional P&C franchise that has converted the hard-market cycle into real cash rather than just accounting earnings. Revenue climbed from $10.01B in 2023 to $12.63B in 2025 while net income rose from $1.84B to $2.39B; trailing free cash flow of $3.09B against a $26.15B market cap produces an ~11.8% FCF yield at $170.39. The balance sheet is fortress-grade—$861M debt against $15.91B equity (D/E 0.054) and $1.43B cash—so the 2.2% dividend (22% payout) is not under genuine threat. ROE of 15% and a 19% net margin at 11.2× earnings and 1.69× book are the profile of a mature earner that the market is treating as zero-growth; the 12.3% revenue CAGR and 23% FCF CAGR of recent years contradict that pricing. Quarterly volatility is real—margins swung from –3.5% in early 2025 to 29–30% in strong quarters—but that is the insurance business, not evidence of structural decay. The model output claiming $516–$593 fair value is simply broken; a sensible capitalization of $3B sustainable FCF at a 9–10% cost of equity with modest growth lands closer to the low-to-mid $200s, implying the stock is cheap but not a three-bagger.
The cleanest read is therefore modest undervaluation driven by cycle skepticism rather than fundamental impairment. At 1.69× book and mid-teens ROE the multiple is roughly in line with a 9–10% cost of equity, so the margin of safety lives in the cash-flow yield and the still-elevated rate environment supporting investment income, not in some phantom DCF. Insider activity is mixed and negligible; the “net buying” signal is noise. Sector-relative strength and strong cash conversion matter more than the decelerating quarterly revenue label, which still shows double-digit year-on-year growth.
The strongest opposing case is straightforward catastrophe and cycle risk. A soft-market turn or a heavy CAT year can erase underwriting profit in a single quarter, exactly as 2022’s –$487M net loss and the early-2025 loss quarter demonstrated. The market’s 11× multiple and implied low-growth FCF trajectory explicitly price that mean-reversion; if combined ratios normalize higher and investment yields compress, the 15% ROE and $3B FCF both shrink, and a 1.7× book multiple becomes full rather than cheap. The narrative layer’s claim that the dividend streak is “under pressure” is overstated given the 22% payout, but a multi-year soft market could still force slower dividend growth and multiple compression. I weigh this less heavily because leverage is almost nonexistent, the payout leaves enormous cushion, and current pricing already embeds stagnation; the risk is real but largely discounted.
What flips the view: two consecutive quarters of combined-ratio deterioration into the mid-90s or higher with FCF falling below $2B would push me to fairly valued or worse; conversely, another year of mid-teens ROE and FCF holding near $3B while the hard market persists would justify a move toward $210–230 and a more aggressive stance.
Big-3 Panel — where each AI stands
Advanced Analysis Forensic deep-dive · separate lenses
Revenue has climbed from $9.63B (2021) through a $6.56B trough in 2022 (a year that also produced a $487M net loss, almost certainly investment-portfolio mark-to-market driven, given P&C accounting quirks) to $12.63B in 2025, with net income recovering to $2.39B and FCF stepping up every year to $3.09B. Diluted share count has drifted from 164.0M to 157.7M (roughly -1%/yr CAGR), and buybacks dwarf SBC by ~2885x, so per-share value is being concentrated rather than diluted. Liquid cash of $1.58B plus $718M net cash and strong operating cash generation mean the business self-funds comfortably.
Verify before trusting this (5)
- Combined ratio trend 2021-2025 to confirm underwriting (not just investment income) is driving the recovery
- Composition of the investment portfolio (equity vs fixed income mix) that caused the 2022 loss
- Reserve development history (favorable vs adverse) to gauge reserving conservatism
- Catastrophe exposure and reinsurance program given rising FCF could mask cat-year variance
- Details of the buyback authorization and pace vs dividend policy
The e2e composite fair value of $516 and signal-adjusted $592 imply a 3x+ upside from $170.39 that no serious P&C insurer commands. The DCF at $622 is almost certainly a runaway - CINF's earnings are dominated by an equity-heavy investment portfolio (evidenced by the 2022 GAAP loss on flat operations) and mark-to-market swings do not discount cleanly. I discard it. The anchored-PE at $303 is more grounded but still generous given weak earnings quality (haircut hint: -1) and cyclical combined-ratio pressure. Haircutting for earnings volatility and cycle risk, a deserved value in the $170-$200 range is defensible for a durable but slow-growing regional P&C compounder trading at typical book/earnings multiples for the group. Against $170.39, that is roughly fair - maybe a small discount, not a mispricing. The strong business quality (rising FCF to $3.09B, net cash, shrinking share count, 60+ year dividend streak) supports the deserved value but is already reflected in the price of a well-known widow-and-orphan name. No margin of safety worth acting on; also no reason to call it rich.
Verify before trusting this (4)
- Current GAAP vs operating earnings split - how much of reported EPS is investment mark-to-market vs underwriting
- Recent combined ratio trend and pricing commentary in commercial lines
- Investment portfolio equity concentration and any repositioning
- Management guidance on dividend sustainability if underwriting deteriorates
The macro tape is essentially neutral (regime score -3, VIX 16, S&P just 2% off highs) and CINF's 0.55 beta means even a risk-off lurch would barely register here. This is a low-cult, low-intensity steady-compounder name - it does not trade on narrative energy, so there is no story to collapse and no mania to unwind. The active narrative is fragile but minimal in intensity, meaning sentiment simply is not doing much work on this stock in either direction. What flow does exist skews mildly positive: a director bought 1,000 shares at $171.64 (a small but visible insider signal), and CINF is being featured in dividend-aristocrat listicles highlighting its 60+ year dividend streak through prior crashes - exactly the kind of press that attracts income-oriented buyers in an uncertain tape. Against that, higher-for-longer rates (10y at 4.75%) and a stretched market PE are a generic headwind for insurers via investment-yield and duration concerns, and the bear whisper about combined-ratio pressure is a slow, low-grade drag rather than an active de-rating. Net: gentle cross-currents, no dominant force.
Verify before trusting this (4)
- Any Q3 combined-ratio print or cat-loss guidance that could activate the dormant underwriting-cycle bear story
- Whether the 10y pushes above 5% - would meaningfully pressure insurer investment portfolios and the sector bid
- Analyst target revisions or downgrades that would signal the bear whisper is going mainstream
- Further insider buying or selling as a real-time sentiment tell on a quiet name
P&C is exiting a hard market: three years of rate increases built a margin cushion (+4.8pp industry net margin) that is now being competed away in standard commercial lines, while personal lines rate adequacy has largely been restored. The result is a category that still shows positive revenue growth on earned premium but a deteriorating forward demand signal. Against that, a 4.75% 10-year with a 0.41 curve is unambiguously good for an insurer's float: reinvestment yields exceed the book yield, so investment income grows mechanically for several more years regardless of underwriting. CINF's differentiator is structural — a distribution model that adds premium by adding and deepening agency relationships — which is the right engine to own when price is no longer doing the work. Cat frequency and social inflation are the two exogenous variables that can overwhelm all of it in any given quarter.
When we made this prediction on Sep 2, 2026, CINF was $171.86. We expect it to be $193.50 by Mar 2027, and we consider it great value under $145.00. This is an early model (v0.6.0) — the direction is more reliable than the exact price. Made Sep 2, 2026.
Blue is our prediction, starting the day we made it. Grey is a slower route to the same place — the same destination, taking longer. Black is the actual price, so you can see how we are doing.